NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fiserv, Inc. ("Fiserv, Inc." or the "Company") (NYSE: FI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fiserv, Inc. investors who were adversely affected by alleged securities fraud between July 24, 2024 and July 22, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form?p ...

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=159018&wire=4 NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class ...

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc ("Reckitt Benckiser Group plc" or the "Company") (OTCQX: RBGLY) of a class action securities lawsuit. WHAT'S NEXT? If you suffered a loss in Reckitt Benckiser Group plc during the relevant time frame, you have until August 4, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. CLASS DEFINITION: The l ...

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-for ...

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: WHY LEVI & KORSINSKY: Over the past 20 years, the ...

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sable Offshore Corp. ("Sable Offshore Corp." or the "Company") (NYSE: SOC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sable Offshore Corp. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June 3, 2 ...

VSTS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 www.zlk.com CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing ...

Core Viewpoint - Everest Medicines has made a strategic equity investment of US$30.9 million in I-Mab, acquiring a 16.1% ownership stake, which aligns with its focus on next-generation oncology programs and enhances its presence in the U.S. market [1][4]. Investment Details - The investment will be made through the subscription of 15,846,154 American Depositary Shares (ADSs) at an offering price of $1.95 per ADS, contributing to total gross proceeds of approximately US$65 million for I-Mab [5]. - Following the investment, Everest will hold a total of 15,846,154 ADSs and 6,078,571 ordinary shares of I-Mab, representing approximately 16.1% of I-Mab's total issued share capital [5]. Clinical Development Synergies - I-Mab's bispecific antibody pipeline, particularly the 4-1BB receptor targeting platform, is complementary to Everest's existing mRNA cancer vaccines and in vivo CAR-T platform, potentially accelerating the development of pipeline products for both companies [2][3]. - The collaboration may leverage I-Mab's clinical translational capabilities in the U.S. and Everest's clinical capabilities in Asia, enhancing the global expansion of their respective product pipelines [3][4]. Product Pipeline - I-Mab's key pipeline products include Givastomig (Claudin 18.2 x 4-1BB bispecific antibody), which has shown an overall response rate (ORR) of 83% in a Phase 1b trial for first-line gastric cancers [1][9][13]. - Other notable candidates in I-Mab's pipeline include Ragistomig (PD-L1 x 4-1BB bispecific antibody) and Uliledlimab (CD73 antibody), indicating a strong focus on precision immuno-oncology agents [8][13]. Company Background - Everest Medicines is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics, particularly in oncology, renal diseases, infectious diseases, and autoimmune disorders [11]. - I-Mab is a U.S.-based global biotech company focused on precision immuno-oncology, with a differentiated pipeline aimed at treating various cancers [8][13].

Sales Performance - Hyundai Motor America reported total sales of 79,543 units in July 2025, marking a 15% increase compared to July 2024 and setting an all-time July record [1][3] - Retail sales rose 18% to 73,064 units compared to July 2024, with electrified vehicles representing 32% of the retail sales mix [2][3] - Electrified vehicle sales surged 50% compared to July 2024, indicating strong momentum in sustainable mobility [1][3] Model Performance - Significant sales increases were observed in several models: IONIQ 5 retail sales increased by 71%, Santa Fe family sales rose by 54%, and Palisade sales climbed by 59% [2][3] - The Elantra HEV, Elantra N, Santa Fe HEV, Palisade, IONIQ 5, and Santa Fe family all set total sales records in July [1][3] Year-to-Date Performance - Year-to-date total sales for 2025 reached 518,823 units, an 11% increase from 468,725 units in 2024 [4] - The year-to-date performance for specific models includes a 15% increase in Elantra sales and a 12% increase in IONIQ 5 sales [7] Corporate Recognition and Initiatives - Hyundai Motor Group was recognized by TIME magazine as an "Automotive Darkhorse" in the "100 Most Influential Companies of 2025" [6] - The company launched a new customer rewards program, Hyundai Rewards, aimed at enhancing customer experience [6]

PHILADELPHIA, Aug. 1, 2025 /PRNewswire/ -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses.Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, ...